medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-12-154-160medsovet-2048Research ArticleТРОМБОЗЫ И ТРОМБОЭМБОЛИИTHROMBOSIS AND THROMBOEMBOLISMПРОФИЛАКТИКА ИНСУЛЬТА ПРИ НЕКЛАПАННОЙ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ. О ЧЕМ ГОВОРЯТ РЕЗУЛЬТАТЫ ИССЛЕДОВАНИЯ ROCKET AFSTROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION. WHAT ROCKET AF STUDY RESULTS SAYЯвеловИ. С.YavelovI. S.

 д.м.н., в.н.с. отдела клинической кардиологии и молекулярной генетики 

 

PhD in medicine, leading research associate of the clinical cardiology and molecular genetics department 

 

Государственный научно-исследовательский центр профилактической медицины Минздрава РоссииРоссияState Scientific and Research Center of Preventive Medicine of the Ministry of Health of RussiaRussian Federation201704112017012154160Copyright © Явелов И.С., 20172017Явелов И.С.Yavelov I.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2048

Длительное (неопределенно долгое) применение пероральных антикоагулянтов – наиболее действенный способ медикаментозного предупреждения кардиоэмболических осложнений при фибрилляции предсердий (ФП). Этот подход превосходит по эффективности антиагреганты (как монотерапию ацетилсалициловой кислотой, так и ее сочетание с клопидогрелом). В этом сообщении будут представлены факты, определившие представления о месте одного из пероральных антикоагулянтов прямого действия – ривароксабана – в профилактике кардиоэмболических осложнений у больных с неклапанной ФП. Речь идет о рандомизированном контролируемом исследовании ROCKET AF, результаты которого стали основанием для одобрения ривароксабана к широкому применению при неклапанной ФП.

 

 

 

 

Long-term (indefinitely long) use of oral anticoagulants is the most efficient method of medical prevention of cardioembolic complications of atrial fibrillation (AF). This approach is superior to the effectiveness of antiplatelet agents (as monotherapy by acetylsalicylic acid and its combination with clopidogrel). This summary will present the facts that determined ideas about the place of one of the oral anticoagulants of direct action – rivaroxaban – in the prevention of cardioembolic complications in patients with non-valvular atrial fibrillation. We are talking about a randomized, controlled study ROCKET AF, the results of which became the basis for the approval of rivaroxaban for widespread use in non-valcular atrial fibrillation.

неклапанная фибрилляция предсердийинсультисследование ROCKET AFривароксабанnon-valvular atrial fibrillationstrokeROCKET AF studyrivaroxabanReferencesYou JJ, Singer DE, Howard PA et al. Antithrombotic Therapy for Atrial Fibrillation. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(Suppl): e531S-e575S.You JJ, Singer DE, Howard PA et al. Antithrombotic Therapy for Atrial Fibrillation. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(Suppl): e531S-e575S.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 2016, 37: 2893-2962.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 2016, 37: 2893-2962.2014 AHA/ACC/HRS Guidelines for theManagement of Patients With Atrial Fibrillation. JACC, 2014, 64: 2246-2280.2014 AHA/ACC/HRS Guidelines for theManagement of Patients With Atrial Fibrillation. JACC, 2014, 64: 2246-2280.Hart RG, Benavente O, McBride R, Pearce LA.Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis. Ann Intern Med, 1999, 131: 492-501.Hart RG, Benavente O, McBride R, Pearce LA.Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis. Ann Intern Med, 1999, 131: 492-501.Hart RG, Pearce LA, Aguilar MI. Meta-analysis:Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med, 2007, 146: 857-867.Hart RG, Pearce LA, Aguilar MI. Meta-analysis:Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med, 2007, 146: 857-867.Connolly SJ, Eikelboom J, Joyner C et al, for theAVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med, 2011, 364: 806-817.Connolly SJ, Eikelboom J, Joyner C et al, for theAVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med, 2011, 364: 806-817.The ACTIVE Writing Group on behalf of theACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, 2006, 367: 1903-1912.The ACTIVE Writing Group on behalf of theACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, 2006, 367: 1903-1912.Hohnloser SH, Pajitnev D, Pogue J et al, for theACTIVE W Investigators. Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy. An ACTIVE W Substudy. JACC, 2007, 50: 2156-2161.Hohnloser SH, Pajitnev D, Pogue J et al, for theACTIVE W Investigators. Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy. An ACTIVE W Substudy. JACC, 2007, 50: 2156-2161.Heidbuche H, Verhamme P, Alings M et al.European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2013, 15: 625-651.Heidbuche H, Verhamme P, Alings M et al.European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2013, 15: 625-651.Granger CB, Alexander JH, McMurray JJ et al, for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011, 365: 981-992.Granger CB, Alexander JH, McMurray JJ et al, for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011, 365: 981-992.Connolly SJ, Connolly SJ, Ezekowitz MD et al, for the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009, 361: 1139-1351.Connolly SJ, Connolly SJ, Ezekowitz MD et al, for the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009, 361: 1139-1351.Patel MR, Mahaffey KW, Garg J et al, for theROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011, 365: 883-891.Patel MR, Mahaffey KW, Garg J et al, for theROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011, 365: 883-891.Breithardt G, Baumgartner H, Berkowitz SD et al, for the ROCKET AF Steering Committee & Investigators. Characteristics and Outcomes of Patients with Atrial Fibrillation and Significant Valvular Lesions: Experience from the ROCKET AF Trial. JACC, 2013, 61(supplement): E339.Breithardt G, Baumgartner H, Berkowitz SD et al, for the ROCKET AF Steering Committee & Investigators. Characteristics and Outcomes of Patients with Atrial Fibrillation and Significant Valvular Lesions: Experience from the ROCKET AF Trial. JACC, 2013, 61(supplement): E339.Breithardt G, Berkowitz SD, Baumgartner H et al, for the ROCKET AF Steering Committee & Investigators. Outcomes of Patients with Atrial Fibrillation and Significant Valvular Lesions: Comparison of the Effects of Rivaroxaban and Warfarin in the ROCKET AT Trial. JACC, 2013, 61(supplement): E339.Breithardt G, Berkowitz SD, Baumgartner H et al, for the ROCKET AF Steering Committee & Investigators. Outcomes of Patients with Atrial Fibrillation and Significant Valvular Lesions: Comparison of the Effects of Rivaroxaban and Warfarin in the ROCKET AT Trial. JACC, 2013, 61(supplement): E339.Patel MR, Hellkamp AS, Lokhnygina Y et al.Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). JACC, 2013, 61: 651-658.Patel MR, Hellkamp AS, Lokhnygina Y et al.Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). JACC, 2013, 61: 651-658.Sherwood MW, Nessel CC, Hellkamp AS et al.Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin ROCKET AF Trial. JACC, 2015, 66: 2271-2281.Sherwood MW, Nessel CC, Hellkamp AS et al.Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin ROCKET AF Trial. JACC, 2015, 66: 2271-2281.Mahaffey KW, Stevens SR, White HD et al, for the ROCKET AF Investigators. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J, 2014, 35: 233-241.Mahaffey KW, Stevens SR, White HD et al, for the ROCKET AF Investigators. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J, 2014, 35: 233-241.Hankey GJ, Patel MR, Stevens SR et al, for the ROCKET AF Steering Committee and Investigators. Rivaroxaban compared with war-farin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol, 2012, 11: 315-322.Hankey GJ, Patel MR, Stevens SR et al, for the ROCKET AF Steering Committee and Investigators. Rivaroxaban compared with war-farin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol, 2012, 11: 315-322.Fox KAA, Piccini JP, Wojdyla D et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J, 2011, 32: 2387-2394.Fox KAA, Piccini JP, Wojdyla D et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J, 2011, 32: 2387-2394.Lindner SM, Fordyce CB, Hellkamp AS et al, on behalf of the ROCKET AF Steering Committee and Investigators. Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin. A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. Circulation, 2017, 135: 1001-1003.Lindner SM, Fordyce CB, Hellkamp AS et al, on behalf of the ROCKET AF Steering Committee and Investigators. Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin. A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. Circulation, 2017, 135: 1001-1003.Fordyce CB, Hellkamp AS, Lokhnygina Y on behalf of the ROCKET AF Steering Committee and Investigators. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin. Insights From ROCKET AF. Circulation, 2016, 134: 37-47.Fordyce CB, Hellkamp AS, Lokhnygina Y on behalf of the ROCKET AF Steering Committee and Investigators. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin. Insights From ROCKET AF. Circulation, 2016, 134: 37-47.Jones WS, Hellkamp AS, Halperin J et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J, 2014, 35: 242-249.Jones WS, Hellkamp AS, Halperin J et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J, 2014, 35: 242-249.Piccini JP, Hellkamp AS, Washam JB et al. Polypharmacy and the Efficacy and Safety of Rivaroxaban versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation, 2016, 133: 352-360.Piccini JP, Hellkamp AS, Washam JB et al. Polypharmacy and the Efficacy and Safety of Rivaroxaban versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation, 2016, 133: 352-360.

The authors declare that there are no conflicts of interest present.